Phio Pharmaceuticals (PHIO) Retained Earnings (2011 - 2026)
Phio Pharmaceuticals' (PHIO) quarterly Retained Earnings came in at -$159.1 million in Q1 2026, down 7.38% YoY from -$171.7 million in Q1 2025, and down 190.79% on a QoQ basis from $175.2 million in Q4 2025.
Phio Pharmaceuticals (PHIO) Retained Earnings (2011 - 2026) Analysis & Trends
Phio Pharmaceuticals (PHIO) has 16 years of Retained Earnings data on file, last reported at -$159.1 million in Q1 2026.
- Quarterly Retained Earnings fell 7.38% year-over-year to -$159.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$159.1 million (down 7.38% YoY) and the FY2025 annual result came in at $175.2 million, up 15.97% from the prior year.
- Retained Earnings retreated to -$159.1 million in Q1 2026, from $175.2 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $175.2 million in Q4 2025 to a low of -$159.1 million in Q1 2026.
- A 5-year average of -$38.5 million and a median of -$132.0 million in 2023 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2022 — Retained Earnings surged 219.09% — and 2024, when it plunged 199.15%.
- Tracing PHIO's Retained Earnings over 5 years: stood at $139.2 million in 2022, then advanced by 5.54% to $146.9 million in 2023, then rose by 2.82% to $151.1 million in 2024, then increased by 15.97% to $175.2 million in 2025, then tumbled by 190.79% to -$159.1 million in 2026.
- The last three Retained Earnings figures came in at -$159.1 million (Q1 2026), $175.2 million (Q4 2025), and -$152.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -6.33 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 6.57 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 4.38 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 20.91 Bn |
| 10 | Phio Pharmaceuticals | 14.06 Mn | 14.06 Mn | - | 175.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 175.80 Mn |
| Mar 31, 2026 | -159.06 Mn |
| Dec 31, 2025 | 175.20 Mn |
| Sep 30, 2025 | -152.68 Mn |
| Jun 30, 2025 | -150.29 Mn |
| Mar 31, 2025 | -148.13 Mn |
| Dec 31, 2024 | 151.08 Mn |
| Sep 30, 2024 | -144.73 Mn |
| Jun 30, 2024 | -143.21 Mn |
| Mar 31, 2024 | -141.36 Mn |
| Dec 31, 2023 | 146.94 Mn |
| Sep 30, 2023 | -137.31 Mn |
| Jun 30, 2023 | 144.44 Mn |
| Mar 31, 2023 | -131.98 Mn |
| Dec 31, 2022 | 139.22 Mn |
| Sep 30, 2022 | 139.18 Mn |
| Jun 30, 2022 | -122.07 Mn |
| Mar 31, 2022 | -119.54 Mn |
| Dec 31, 2021 | -116.90 Mn |
| Sep 30, 2021 | 138.69 Mn |